Long-term Fluoroquinolone Use Before the Prostate Biopsy May Increase the Risk of Sepsis Caused by Resistant Microorganisms

Akduman, Bülent; Akduman, Deniz; Tokgöz, Hüsnü; Erol, Bülent; Turker, T.; Ayoğlu, Ferruh Niyazi; Mungan, N.A.

doi:10.1016/j.urology.2011.02.065

Cited by 66 publications

(43 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…After prostate biopsy, the infection rate is 2-3%, but positive culture for FREc in these patients is 55% [16] . In other studies, FREc is 100% positive in cultures and 55.6% of them are positive for extended-spectrum lactamases [19] . Recently, Lange et al [20] reported an incidence of 96% FREc with post-biopsy sepsis.…”

Section: Discussionmentioning

confidence: 69%

“…Positive urine culture rates for FREc were similar to the results of previous studies [16] . Increasing resistance rates to fluoroquinolones in E. coli is a serious problem and fluoroquinolone-resistant infections after TRUSBP are increasing [9,19,21] . None of the patients receiving fosfomycin prophylaxis had a positive urine culture for FREc.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The Effectiveness of Single-Dose Fosfomycin as Antimicrobial Prophylaxis for Patients Undergoing Transrectal Ultrasound-Guided Biopsy of the Prostate

Ongün¹,

Aslan²,

Avkan-Oğuz

2012

Urol Int

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 69%

Section: Discussionmentioning

confidence: 99%

The Effectiveness of Single-Dose Fosfomycin as Antimicrobial Prophylaxis for Patients Undergoing Transrectal Ultrasound-Guided Biopsy of the Prostate

Ongün¹,

Aslan²,

Avkan-Oğuz

2012

Urol Int

View full text Add to dashboard Cite

show abstract

“…Loeb and colleagues [9] reported that 1.1% of 17,472 patients underwent prostate biopsy required hospitalization for infection-related complications and they also reported the increase in infectious complications after prostate biopsy in recent years while the rate of serious noninfectious complications is relatively stable. A number of studies have identified potential risk factors for infectious complications of post-prostate biopsy The most common of these risk factors appears to be exposure to antimicrobials within 6 months prior to biopsy [11], presence of fluoroquinolone resistant E. coli strains in fecal flora [12] and recent international travel [13]. The fluoroquinolone-resistance rate in E.coli-associated urinary tract infections has been reported to be about 10% [14].…”

Section: Discussionmentioning

confidence: 99%

Ciprofloxacin-Ceftriaxone Combination Prophylaxis for Prostate Biopsy; Infective Complications

Özorak¹

2015

Ann Clin Anal Med

View full text Add to dashboard Cite

ÖzetAmaç: Siprofloksasin ve seftriakson (üçüncü kuşak sefalosporin) kombinasyon profilaksisi altında, ultrasonografi kılavuzluğunda transrektal prostat biyopsisi uyguladığımız hastalarda gelişen enfektif komplikasyonları sunduk. Gereç ve Yöntem: Çalışmaya biyopsiden 1 saat önce intramuskuler 1 g seftriakson ve biyopsi sonrası 5 gün, günde iki doz, oral 500 mg siprofloksasin uygulanan 1193 hasta dahil edildi. Biyopsi öncesi rutin idrar analizi ve idrar kül-türü alınmadı. Akut prostatit ve ürosepsis gibi ciddi enfektif komplikasyonlar ve neden olan mikroorganizmalar değerlendirildi. Bulgular: Hastaların 16 (%1,3)'sında ciddi enfektif komplikasyonlar gelişti. Onbeş hastaya akut prostatit teşhisi konuldu ve 15 hastanın 10'unda idrar kültüründe Escherichia coli pozitif bulundu. Suşlar siprofloksasine dirençliydi. Sadece 1 hastada ürosep-sis gelişti. Bu hastanın kan ve idrar kültüründe siprofloksasine dirençli genişletilmiş spektrumlu β-laktamaz üreten (ESBL) Escherichia coli tespit edildi. Hiçbir hastada antibiyotiklere bağlı yan etki gözlenmedi. Tartışma: Belirli bir profilaksi prosedürü olmamasına rağmen transrektal prostat biyopsi profilaksisinde siprofloksasin en yaygın kullanılan antibiyotiktir. Bununla birlikte siprofloksasin dirençli Escherichia coli suş insidansı artmaktadır. Bu nedenle yeni profilaksi stratejileri tartışılmalıdır. Seftriakson ile siprofloksasin kombinasyon profilaksisi prostat biyopsisinde güvenli ve kullanılabilir bir seçenektir. Anahtar Kelimelerİnfeksiyon; Profilaksi; Prostat Biyopsisi; Seftriakson; Siprofloksasin Abstract Aim: To present our clinical experience about infective complications due to ultrasound guided transrectal prostate biopsy under ciprofloxacin plus thirdgeneration cephalosporin (Ceftriaxone) combination prophylaxis. Material and Method: The 1193 patients that used combination of ceftriaxone 1 g intramuscular 1 hour before biopsy and ciprofloxacin 500 mg twice a day for 5 days after biopsy were included to study. Before biopsy, urine analysis and urinary cultures were not performed routinely. Serious infective complications such as acute prostatitis and urosepsis, causing microorganisms were evaluated. Results: Serious infective complications occurred in (1.3%) 16 patients. Fifteen of them had acute prostatitis and urine culture results were positive in 10/15 patients for Escherichia coli. The strains were uniformly resistant to ciprofloxacin. Only 1 patient had urosepsis and his blood and urine cultures demonstrated extended-spectrum β-lactamase-producing (ESBL) Escherichia coli also resistant to ciprofloxacin. Antibiotic treatment-related side effects were not observed in any patient. Discussion: Although there is not a certain procedure, ciprofloxacin is the most common used antibiotic for transrectal prostate biopsy prophylaxis. On the other hand, the incidence of ciprofloxacin resistant Escherichia coli strain is increasing. Thus, new prophylaxis strategies have to be discussed. Ceftriaxone plus ciprofloxacin prophylaxis is safe and can be useable option for prophy...

show abstract

“…Exposure to antimicrobial agents in the 6 months prior to biopsy has been identified in several studies as a risk factor for infection (23)(24)(25). Increased risk has also been seen in hospital employees and their family members and people who have traveled internationally (24,(26)(27)(28).…”

Section: Risk Factors For Postbiopsy Infectionmentioning

confidence: 99%

Cutting to the Core of the Issue: Emerging Strategies To Reduce Prostate Biopsy-Related Infections

Chamberland

2016

J Clin Microbiol

View full text Add to dashboard Cite

Over 1 million men undergo biopsy in the United States each year to evaluate for prostate cancer (S. Loeb, H. B. Carter, S. I. Berndt, W. Ricker, and E. M. Schaeffer, J Urol 186:1830–1834, 2011,http://dx.doi.org/10.1016/j.juro.2011.06.057). In recent years, there has been a rise in infectious complications related to these procedures. This review aims to provide an overview of the guidelines that direct transrectal prostate biopsy, to describe associated infection, and to evaluate the published data driving the current trend toward prebiopsy screening for resistant organisms.

show abstract

Long-term Fluoroquinolone Use Before the Prostate Biopsy May Increase the Risk of Sepsis Caused by Resistant Microorganisms

Cited by 66 publications

References 23 publications

The Effectiveness of Single-Dose Fosfomycin as Antimicrobial Prophylaxis for Patients Undergoing Transrectal Ultrasound-Guided Biopsy of the Prostate

The Effectiveness of Single-Dose Fosfomycin as Antimicrobial Prophylaxis for Patients Undergoing Transrectal Ultrasound-Guided Biopsy of the Prostate

Ciprofloxacin-Ceftriaxone Combination Prophylaxis for Prostate Biopsy; Infective Complications

Cutting to the Core of the Issue: Emerging Strategies To Reduce Prostate Biopsy-Related Infections

Contact Info

Product

Resources

About